The U.S. Centers for Medicare & Medicaid Services just expanded its drug pricing battleground in a pretty significant way. The agency announced 15 high-cost prescription drugs selected for the third cycle of Medicare's Drug Price Negotiation Program, and here's what makes this round different: it's the first time the initiative includes drugs reimbursed under Medicare Part B.
That might sound like bureaucratic alphabet soup, but it matters. Part B covers physician-administered treatments, the kind you get in a doctor's office or hospital rather than picking up at the pharmacy. Previous negotiation rounds focused exclusively on Part D drugs, the ones you take home in a bottle. So this represents a meaningful expansion of what Medicare can haggle over.
The medications on the list treat a wide range of serious conditions including cancer, psoriatic arthritis, and HIV-1 infection. According to CMS, negotiations with participating drugmakers will take place in 2026, with any agreed-upon prices scheduled to kick in on January 1, 2028. The agency also selected one previously negotiated drug for its first renegotiation under the program, which suggests this isn't just a one-and-done process.
Expanding Beyond Pharmacy Counter Drugs
The move builds on earlier negotiation cycles that stuck to Medicare Part D drugs. Now, by including treatments typically covered under Part B, the program reaches into a different segment of healthcare spending. Think cancer infusions, injectable medications for autoimmune conditions, and other treatments administered by healthcare professionals rather than self-administered at home.
CMS framed the announcement as a continuation of efforts launched under President Donald Trump to control prescription drug costs for seniors and taxpayers. During the second negotiation cycle, Medicare successfully reached agreements with manufacturers on all 15 selected drugs. Those negotiated prices are set to take effect on January 1, 2027.
The projected savings are substantial. CMS estimated that if the second-cycle negotiated prices had been in place during 2024, Medicare would have saved approximately $8.5 billion in net covered prescription drug costs, including spending under the Coverage Gap Discount Program. That translates to roughly 36% lower net spending across those selected drugs, which is a meaningful chunk of change in the healthcare budget.
Following the Money
"For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs," said Dr. Mehmet Oz, administrator of CMS. He emphasized that the agency is targeting the most expensive drugs in Medicare to negotiate fair prices and deliver savings while strengthening accountability across the program.
The numbers behind this round's selections are eye-opening. Between November 2024 and October 2025, about 1.8 million Medicare beneficiaries with Part D or Part B coverage used the 15 drugs selected for initial negotiation. Those medications generated roughly $27 billion in total prescription drug spending under Medicare Parts B and D, accounting for approximately 6% of total spending across both programs.
Alongside the announcement, CMS released a list of 50 negotiation-eligible drugs ranked by combined spending under Parts B and D. The 15 drugs chosen for the third negotiation cycle represent the highest-spending medications on that list, which makes sense from a bang-for-your-buck perspective. Why negotiate over small-potato drugs when you can tackle the budget-busters?
"The publication of the list of top 50 negotiation-eligible drugs evidences CMS' commitment to transparency," said Chris Klomp, CMS deputy administrator and director of Medicare.
The Lineup: Who Made the List
The selected drugs for the third cycle of negotiations read like a who's who of pharmaceutical blockbusters. Here's what made the cut:
The drug selected for renegotiation is Boehringer Ingelheim's Tradjenta (linagliptin) for type 2 diabetes. This marks the first time a previously negotiated drug is going back to the table, establishing what could become a regular review process for negotiated prices.
The inclusion of blockbuster names like Botox alongside critical cancer treatments and HIV medications shows the breadth of what Medicare spends money on. Some of these are life-saving therapies with limited alternatives, while others face more competition in their therapeutic categories. How negotiations play out will likely depend heavily on those market dynamics, though the process is still relatively new and everyone's figuring out the rules as they go.
For pharmaceutical companies, this represents continued pressure on pricing power for their most profitable products. For Medicare beneficiaries and taxpayers, it's a bet that the government can use its purchasing power to bring down costs without disrupting access to important medications. The 2028 implementation date gives everyone plenty of time to adjust, negotiate, and probably argue about whether this whole experiment is working as intended.
